Flu vaccines have surged in volume, and vaccine companies will outperform expectations

"Pharmaceutical Network Industry Dynamics" Influenza is an acute respiratory infection caused by influenza virus, characterized by seasonal epidemics.
the flu season, there are 3 to 5 million serious cases in China, resulting in 290,000 to 650,000 respiratory disease-related deaths.
In order to prevent and control influenza, the National Influenza Prevention and Control Program (Trial) issued by the National Health And Health Commission at the end of 2018 proposed five measures, including strengthening epidemic surveillance and adjudication, strengthening the application of influenza vaccines, strengthening outbreak prevention and control in key locations, strengthening the handling of outbreaks and strengthening medical treatment.
in the Influenza Diagnosis and Treatment Program (2019 edition), the National Health and Safety Commission also asked all types of medical institutions at all levels in accordance with the new program to further improve the level of standardized influenza diagnosis and treatment.
clearly, influenza vaccination is an important way and effective means to prevent influenza and stop influenza transmission.
Against this background, industry experts believe that in the context of the 2020 epidemic, people's recognition of vaccines has greatly increased, China's influenza vaccine market will usher in a new round of development opportunities, the performance of related enterprises will also be high-speed growth.
It is understood that China's influenza vaccine enterprises have been restored from 5 in 2019 to 8: Hualan Biological, Shanghai Institute, Changchun Institute, Beijing Kexing, Sanofi Pasteur, Jindik Bio, Changchun Baike, Dalian Yalifeng Biopharmaceuticals, products include four-price vaccine, triple-price vaccine and freeze-dried nasal spray flu vaccine.
as of September 23rd, the total number of flu vaccines approved by these companies had exceeded 22.36 million, well above the level for the whole of 2019.
of these, Sanofi Pasteur 597.6303 million, Hualan Bio 601.2233 million, Changchun Institute 307.3945 million, Beijing Kexing 307.3847 million;
of the remaining Shanghai more than 500,000, Jindick biological more than 700,000, Dalian Yalifeng biopharmaceutical nearly 200,000.
from the batch can be predicted, the relevant enterprise vaccine sector performance may be higher than in 2019.
fact, earlier this year, several vaccine companies had expressed positive results for 2020.
hualan biology as an example, after its related people have said that according to this year's shortage of influenza vaccines around the country, the company is working overtime to produce influenza vaccines to meet the current shortage everywhere.
is forecast to produce nearly 3 million triple-priced influenza vaccines, and the production of four-priced flu vaccines has increased from 16 million to 20 million.
Some market analysts believe that according to the market price of four-price influenza vaccine 110 yuan / dose to 130 yuan / dose of the winning bid estimate, this year Hualan bio-flu vaccine sector will provide the company with at least 2.2 billion yuan in revenue, far more than last year.
Addition, Changchun Gaoxin released the 2020 semi-annual report also showed that the company's influenza-reducing live vaccine to obtain drug registration approval, enriched the company's vaccine product line, will also bring the company a new profit growth point.
preparations for the listing are now in place, and the bidding process in the provinces is progressing smoothly.
, under the impetus of many factors, the vaccine industry supply and demand, will enter a high boom cycle.
, quality control strict, heavy-weight product pipeline rich head vaccine enterprises will usher in a golden period of release.